VEGFA and glioblastoma: Beside bevacizumab, additional anti-angiogenic monotherapies have been or are being tested in trials for patients with recurrent glioblastoma, such as the VEGF trap aflibercept, which is a recombinant fusion protein that inhibits both VEGF and placental growth factor, and the VEGF receptor (VEGFR) inhibitor cediranib.